VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Soc...
31 Março 2020 - 8:30AM
VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical
company, today announced the accelerated launch of the telemedicine
and remote monitoring modules of the VIVUS Health Platform.
Participating physicians will be able to use the VIVUS Health
Platform to conduct virtual office visits, regardless of whether or
not the patient is prescribed a VIVUS product. The Company
expects to enroll 150-200 physicians into the new modules each
week.
“Effective communication around health
conditions, such as obesity, can be difficult under the best of
circumstances, and are even more challenging in the current
environment in which patients, physicians, and care facilities are
adhering to social distancing guidelines to prevent the spread of
COVID-19. These guidelines also make it difficult for cystic
fibrosis patients, who are at increased risk of COVID-19 due to
their compromised lung function, to consult with their healthcare
providers,” said John Amos, Chief Executive Officer at VIVUS.
“We have rapidly accelerated the launch of our telemedicine
and remote monitoring modules to facilitate communication during
this unprecedented pandemic and ensure that patients can receive
optimum care without leaving their homes.”
The VIVUS Health Platform is designed to
integrate pharmaceutical solutions, technology and clinical
stakeholders to improve patient outcomes through increased
information capture, resulting in enhanced patient access,
increased adoption, and treatment durability. It includes the
VIVUS Advantage Programs, which offer Patient Assistance Programs
to facilitate access to medication for uninsured or underinsured
patients with obesity or exocrine pancreatic insufficiency, and
also allows patients prescribed VIVUS medications to have their
prescriptions filled online and sent directly to their homes.
The telemedicine and remote monitoring modules
are designed to leverage normal clinical practices without
disrupting routine clinical operations. While the
patient-physician interaction takes place virtually through the
VIVUS Health Platform, powered by Vital Tech, all other activities,
such as scheduling, patient administration, billing, etc., take
place utilizing existing clinic processes and resources. The
telemedicine module is configured for easy and rapid activation,
allowing physician offices and clinics to implement the platform
with minimal effort.
Remote patient monitoring is integrated into the
VIVUS Health Platform through the Apple Health Kit, Apple Watch,
and a wide variety of blue tooth-enabled health devices that will
include weight scales, pulse oximeters, spirometers to measure lung
function, and blood pressure cuffs. Data from these devices
and the Apple Health Kit are transmitted and collated directly into
the VIVUS Health Platform, which can be accessed by the patient’s
physician. Physicians can utilize these data to monitor a
patient’s vital functions, and can implement or adapt treatment to
achieve or maintain target goals for important health metrics.
There are no upfront or monthly fees, and
physicians pay a fee only for each telemedicine visit and/or for
remote patient monitoring. The VIVUS Health Platform is also
not limited by a patient’s health insurance plan.
“Obesity is an epidemic in its own right, and in
this time of social distancing, patients may find it more difficult
to adhere to a healthy diet and activity goals. Patients with
cystic fibrosis are challenged day-to-day with the need to avoid
respiratory infections, a challenge that is even more critical
during the COVID-19 pandemic. This pandemic underscores the
critical importance of helping patients manage health conditions
that increase their susceptibility to other diseases,” added
Santosh T. Varghese, MD, Senior Vice President, Chief Medical
Officer at VIVUS. “VIVUS is committed to addressing these
challenges by increasing access to care through telemedicine,
online fulfillment of prescriptions, and data collection from smart
health devices that allow patients and healthcare providers to
monitor health progress in real-time. Additionally, we are
expanding this platform into the clinical trial space as we address
the challenges of conducting studies in this new environment.”
Physicians interested in enrolling in the VIVUS
Health Platform may contact VHP@vivus.com.
About VIVUS
VIVUS is a biopharmaceutical company committed
to the development and commercialization of innovative therapies
that focus on advancing treatments for patients with serious unmet
medical needs. For more information about VIVUS, please visit
www.vivus.com.
Forward-Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995 and are subject to risks,
uncertainties and other factors, including risks and uncertainties
related to our ability to execute on our business strategy to
enhance long-term stockholder value; risks and uncertainties
related to our ability to address our outstanding balance of the
convertible notes due in May 2020; risk and uncertainties related
to the timing, strategy, structure and success of our capital
raising efforts; risks and uncertainties related to the effect of
the recent coronavirus (COVID-19) outbreak on our business and the
businesses of our partners; risks and uncertainties related to the
effectiveness of the VIVUS Health Platform, including its adoption
by healthcare providers and its ability to improve patient outcomes
and, if applicable, access to Qsymia® and PANCREAZE®; risks and
uncertainties related to the timing, strategy, tactics and success
of the marketing and sales of PANCREAZE, including our ability to
improve patient access to PANCREAZE; risks and uncertainties
related to our, or our current or potential partner's, ability to
successfully commercialize Qsymia, including our ability to improve
patient and physician access to Qsymia; risks and uncertainties
related to our ability to sell through the Qsymia retail pharmacy
network and the Qsymia Advantage Program; risks and uncertainties
related to the timing of initiation and completion of the
post-approval clinical studies required as part of the approval of
Qsymia by the U.S. Food and Drug Administration (“FDA”), including
the Phase 4 post-marketing study of Qsymia in obese adolescents;
risks and uncertainties related to the response from FDA to any
data and/or information relating to post-approval clinical studies
required for Qsymia; risks and uncertainties related to the impact
of any possible future requirement to provide further analysis of
previously submitted clinical trial data; risks and uncertainties
related to the design and outcome of any clinical study required by
FDA to expand the Qsymia label; risks and uncertainties related to
our ability to work with FDA to significantly reduce or remove the
requirements of the clinical post-approval cardiovascular outcomes
trial; risks and uncertainties related to the failure to
obtain FDA or foreign authority clearances or approvals
and noncompliance with FDA or foreign authority
regulations; and risks and uncertainties related to our ability to
demonstrate through clinical testing the quality, safety, and
efficacy of our current or future investigational drug candidates
or approved products. These risks and uncertainties could cause
actual results to differ materially from those referred to in these
forward-looking statements. The reader is cautioned not to rely on
these forward-looking statements. Investors should read the
risk factors set forth in VIVUS’ Form 10-K for the year ended
December 31, 2019 as filed on March 3, 2020, and periodic reports
filed with the Securities and Exchange Commission. VIVUS does
not undertake an obligation to update or revise any forward-looking
statements.
VIVUS, Inc. |
Investor Relations: Lazar FINN Partners |
Mark Oki |
David Carey |
Chief Financial Officer |
Senior Partner |
oki@vivus.com |
david.carey@finnpartners.com |
650-934-5200 |
212-867-1768 |
VIVUS (NASDAQ:VVUS)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
VIVUS (NASDAQ:VVUS)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024